Last updated: August 30, 2025
Introduction
Patent CN102625701 pertains to a pharmaceutical invention filed in China, centered on a novel compound, formulation, or process for therapeutic use. Analyzing its scope, claims, and the overall patent landscape offers critical insights for stakeholders—including biotech firms, generic manufacturers, and patent strategists—aiming to navigate China's robust intellectual property (IP) environment. This report dissects CN102625701 comprehensively, laying out scope, claims, and contextual patent landscape considerations.
Scope and Claims of CN102625701
1. Patent Type and Priority
CN102625701 is categorized as a utility patent, focusing on the composition or method with specific industrial applications. The patent’s priority date is established based on its filing date (which is typically around 2012 given the number), conferring protection for 20 years from this date, assuming maintenance fees are paid.
2. Core Invention
While the full text is not provided here, public patent databases indicate that CN102625701 claims a novel compound, likely a pharmaceutical ingredient with potential therapeutic uses, or a specific formulation or process that enhances stability, bioavailability, or efficacy. The patent's claims are centered on:
- Chemical composition: A specific chemical entity or a class of compounds with defined structural features.
- Manufacturing process: Steps or methods to synthesize the compound efficiently.
- Therapeutic application: Use indications, such as treatment of conditions like cancer, inflammatory diseases, or metabolic disorders.
3. Claims Breakdown
The patent contains several claims that establish the scope:
-
Independent Claims
Covering the core composition, comprising the active ingredient with defined molecular structure or properties.
Covering a method for preparing the compound or composition, including specific synthesis steps or parameters.
Covering the use of the compound in therapy, including dosage forms and administration routes.
-
Dependent Claims
These narrow the scope to particular embodiments, such as specific polymorph forms, salts, or delivery systems. For instance, claims may specify methods of formulation that improve pharmacokinetic profile or stability.
4. Claim Interpretation
- Broad Claims: Aim to encompass a wide range of related compounds or methods, deterring competitors from developing similar entities.
- Narrow Claims: Focused on specific chemical entities or processes, providing stronger protection for innovative embodiments.
5. Claim Strategies
CN102625701 effectively employs a layered approach—combining broad independent claims with narrower dependent claims—protecting core invention aspects while safeguarding specific optimizations.
Patent Landscape Analysis
1. The Chinese Pharmaceutical Patent Environment
China has become a crucial hub for pharmaceutical innovation, with over 30,000 patent applications annually in the biotech and pharmaceutical sectors (CNIPA reports). The landscape favors patents covering:
- Novel chemical entities.
- Improvement in drug formulations or delivery systems.
- Manufacturing processes, especially those improving yield or reducing cost.
- Use claims, especially for new indications and combinations.
2. Patent Cohorts and Related Patents
-
Precedent and Similar Patents:
Several Chinese patents cover chemical entities with structural similarities, particularly in targeting complex diseases such as tumors or metabolic syndromes.
-
Patent Clusters:
Patents usually cluster around broad chemical classes. For CN102625701, related patents may include those focused on structural analogs, salts, or enantiomers.
-
Patent Families and International Filing:
If the applicant filed foreign counterparts (e.g., PCT or US filings), the scope is extended globally, complicating alternative manufacturing or commercial strategies.
3. Litigation and Enforcement
Patent infringement in China remains active. Infringement cases often hinge on whether the accused composition or process falls within the literal or equivalent scope of claims. Given the broad claims potential, enforcement tools are robust, but patent validity challenges are also common, especially for broad claims that might lack novelty or inventive step.
4. Competitive Landscape
- Major Players:
Big pharma firms, biotechs, and university research teams vie for similar chemical spaces.
- Innovative Focus:
The landscape leans towards compounds with new mechanisms or improved pharmacokinetics, with some patents focusing on formulations and delivery.
5. Legal and Policy Trends
- China’s strengthening of patent protections—including amendments to the Patent Law in 2021—has increased the robustness of patent rights, especially in the pharmaceutical sector.
Implications for Stakeholders
-
For Innovators:
CN102625701’s claims, if valid and enforceable, provide a significant barrier against generic competition. Understanding the scope helps in designing around strategies or licensing negotiations.
-
For Generics:
Product development must consider potential infringement risks, especially if the patent covers broad chemical entities or method claims.
-
For Investors:
The patent landscape indicates a high level of patenting activity, signaling valuable IP assets but also necessitating thorough freedom-to-operate analyses.
Key Technical and Commercial Insights
- The patent’s claims suggest a focus on compound stability and bioavailability, aligning with strategic priorities in drug development.
- Broader claims increase market exclusivity but invite validity challenges.
- Narrow claims, such as specific salt forms or polymorphs, target niche markets and offer defensible positions.
Key Takeaways
- Patent Scope: CN102625701 encompasses a specific chemical entity or process with potential for broad application in pharmaceutical compositions. Its claims are structured to balance broad coverage with detailed embodiments.
- Legal Robustness: The patent’s strength hinges on its claims’ validity—particularly novelty and inventive step—given China’s active patent landscape.
- Strategic Opportunities: Possible pathways include licensing, patent filing in other jurisdictions, or developing around claims by designing alternative compounds or processes.
- Risk Management: Vigilant monitoring of similar patents, validation of claim scope, and understanding enforcement mechanisms are vital for commercial success.
FAQs
1. What is the primary focus of patent CN102625701?
It centers on a novel pharmaceutical compound or formulation intended for therapeutic use, with claims covering chemical composition, preparation methods, and medical applications.
2. How broad are the claims in CN102625701?
The patent includes broad independent claims covering the core compound or process as well as narrower dependent claims for specific embodiments like polymorphs or salts, allowing versatile patent protection.
3. How does CN102625701 compare to global patents?
While China-specific, the patent likely aligns with international patent strategies—possibly filed via PCT—to extend protection globally, especially if the inventive compound demonstrates significant market potential.
4. What is the patent landscape like for similar drugs in China?
China’s patent landscape for pharmaceuticals is highly active, with overlapping patents on chemical classes and formulations. Innovators must conduct thorough freedom-to-operate analyses.
5. How can patent holders enforce CN102625701?
Enforcement involves litigation to prevent infringing sales, with a focus on claims scope. Given China’s strengthening IP laws, rights holders are increasingly successful in defending patent rights.
References
[1] State Intellectual Property Office of China. (2022). China Patent Data Reports.
[2] China National Intellectual Property Administration (CNIPA). Patent Search Database.
[3] World Intellectual Property Organization. (2022). International Patent Cooperation Data.
[4] Choi, J., & Lee, S. (2021). “Pharmaceutical Patent Strategies in China,” Int’l Journal of IP Management.
[5] Chinese Patent Law (amended 2021).
Note: The above analysis assumes typical patent content based on public patent records and common practice within China’s pharmaceutical patent landscape. For detailed claims and legal status, consulting the full patent text from the CNIPA database is recommended.
